Lonza and Doer Biologics in expression system license deal 15-Dec-2021 By Jane Byrne Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.
Increased demand for CDMO microbial outsourcing services 18-Nov-2021 By Jane Byrne Biotech innovators are looking to CDMOs for their key microbial expertise in order to move their therapies from lab to the market, says Lonza.
Wacker Chemie turns to biopharma during period of uncertainty 12-Jul-2019 By Ben Hargreaves Wacker Biotech looks to corner the microbial expression system niche, as Wacker Chemie’s traditional areas of focus face difficult market conditions.
